Covid-19 roundup: CDC de­bat­ing who should get first avail­able vac­cines; EU in Gilead talks af­ter US gob­bled first remde­sivir dos­es

The fed­er­al gov­ern­ment has now spent bil­lions of dol­lars ac­cel­er­at­ing the de­vel­op­ment of a Covid-19 vac­cine, and yet they’ve re­mained hush-hush on who, pre­cise­ly, would ac­tu­al­ly get in­oc­u­lat­ed once the first dos­es are ap­proved and avail­able. In­ter­nal­ly, though, they have been de­bat­ing it.

The CDC and an ad­vi­so­ry com­mit­tee of out­side health ex­perts have been work­ing since April to de­vise a rank­ing sys­tem that would de­ter­mine who re­ceives a vac­cine and when, The New York Times re­port­ed. The ques­tion of who is first in line for in­oc­u­la­tion is im­por­tant be­cause no mat­ter how many dos­es de­vel­op­ers can make or how quick­ly they can make them, dos­es will still come out in batch­es; 300 mil­lion in­oc­u­la­tions will not ap­pear overnight.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.